Seizing New Opportunities: Pharma’s Roadmap for Smarter Manufacturing

Pharmaceutical companies continue to face a complex landscape. Geopolitical tensions and the pandemic have disrupted supply chains, and yet expectations for increased speed to market are higher than ever. Findings from a recent study conducted by FT Longitude of 400 experts in drug development and manufacturing, as well as input from professionals at GSK, Roche, Merck KGaA (Darmstadt Germany) and Kashiv BioSciences, reveal where drug manufacturing is headed in the next 3-5 years